Idorsia Ltd Cenerimod Phase 3 Initiation Webcast Transcript
Good day, and thank you for standing by. Welcome to the cenerimod Phase 3 Initiation Webcast. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Andrew Weiss. Please go ahead.
Thank you, operator. Good afternoon, good morning to you all. My name is Andrew Weiss. I'm the Head of Investor Relations and Corporate Communications here at Idorsia. I want to welcome everyone to our webcast to discuss the initiation of the Phase 3 program investigating cenerimod for the treatment of systemic lupus erythematosus, which we announced this morning.
With me on the call here in Allschwil are our Chief Scientific Officer, Martine Clozel; and Alberto Gimona, our Head of Global Clinical Development.
Next slide, please. As customary to these calls, we will be making forward-looking statements. You have therefore been appropriately warned about the risks and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |